Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
This article was originally published in The Tan Sheet
Executive Summary
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
You may also be interested in...
Nasacort 24HR Superiority Claims OK Without Head-To-Head Tests – NAD
“Strong scientific consensus with regard to product efficacy” justifies claims that Sanofi’s Nasacort Allergy 24HR is “the most effective OTC medicine for the treatment of nasal allergy symptoms,” NAD determines. Claritin-maker Merck, in its challenge, argued Sanofi needs head-to-head testing to support the claim.
Sanofi’s Allegra Claims Clear NAD Review In Merck’s Second Challenge
The National Advertising Division upholds Sanofi’s claims its Allegra antihistamine is “proven effective even at 8x high pollen levels.”
US FTC Says It’s On ‘Solid Ground’ To Bring Cases Following Notices Of Penalty Offense
The US Federal Trade Commission is "fully prepared" to bring forward cases after issuing hundreds of penalty offense notices in April regarding health claims substantiation, and it is likely to seek injunctive and monetary relief, said Samuel Levine, director of the FTC’s Bureau of Consumer Protection, at the National Advertising Division’s annual conference in Philadelphia.